BACK

Tom Bird

Tom Bird

Partner and Co-Head of North America Transactions

New York Office  |  tom.bird@torreya.com   |   212.257.5806

Tom Bird, a Partner at Torreya, is Co-Head of North America Strategic Transactions Advisory.

Tom has more than 40 years of business development, transaction, and operating experience with global pharmaceutical companies. An expert in branded pharmaceuticals, life science tools, generics products, and pharma manufacturing, he has worked on dozens of life-sciences transactions.

Before joining Torreya in 2007, Tom was Vice President of Corporate Development at Cambrex, where he played a key role in the divestiture of manufacturing plants in Ireland and Belgium, and the sale of Cambrex Bio-Subsidiaries to Lonza. Prior to that, as President of Cambrex’s Biosciences Group, Tom built the BioWhittaker cell biology division into a powerhouse supply business through a combination of organic growth and acquisitions. Tom initially joined Cambrex as President of the Nepera Chemical business. Earlier in his career, he was President of Cuno, a filtration and separation company, and President of the Sherwin Williams Consumer Division.

Tom holds a B.A. from Muhlenberg College.

He is a registered representative with Financial West Group.

Selected Transactions

Alphora Research
Sale of company to
Eurofins Scientific
Undisclosed
June 2017
Selexis
Company sale to
JSR Life Sciences
Undisclosed
June 2017
Durect
License of US rights to Posimir® to
Sandoz
$293 million
May 2017
Wafergen Biosystems
Company sale to
Takara
$35.9 million
March 2017
VistaPharm
Company sale to
Warburg Pincus
$100+ million
December 2015
CombiMatrix
Merger with
Invitae Corporation
$34.9 million
November 2017
Cipher
Sale of US dermatology business to
EPI
$13.6 million
May 2017
MainPointe Pharma
Acquired SLO Niacin® from
Upsher-Smith
Undisclosed
March 2017
MainPointe Pharma
Licensed Nexafed® from
Acura Pharma
Undisclosed
March 2017
Female Health
Has merged with
Aspen Park Pharma
to form
Veru
Undisclosed
November 2016
Cardiome
Licensing of
Dalbavancin from
Allergan
$13 million upfront
May 2016
Acerus Pharma
US license agreement
for NATESTO® to
Aytu BioScience
Up to $45.5 million
($8 million upfront)
April 2016
HealthCare Royalty Partners
Royalty-backed
acquisition financing
for undisclosed
spec pharma
Undisclosed
$100 million
February 2016
ProSolus
Sale to
Mission Pharmacal
Undisclosed
June 2015
Trimel Pharmaceuticals
Acquisition of
Canadian rights to
Estrace® from
Shire
$41 million
July 2014
Correvio
Sale to
Cardiome
19.9% of shares +
$12 million
November 2013
Molecular Insight
Sale for up to
$106 million to
Progenics
$12 million +
milestones
January 2013
SpePharm
Collaboration with
Norgine
Undisclosed
December 2012
Xanodyne
Sale of
Amicar® rights to
Versapharm
Undisclosed
August 2012
Xanodyne
Sale of
Roxicodone® to
Covidien
Undisclosed
August 2012
Xanodyne
Sale of Zipsor® to
Depomed
Undisclosed
June 2012
Amorcyte
Sale to
Neostem
$10 million +
milestones
October 2011
Xanodyne
Sale of
prenatal vitamin
franchise
Undisclosed
Undisclosed
October 2011
Quinnova
Sale of dermatology specialty pharma
business to
Amneal
Undisclosed
December 2010
Three Rivers Pharma
Sale to
Kadmon
$100+ million
October 2010
Columbia Labs
Sale of
Crinone® & Prochieve® product lines and
shares to
Watson
$92.5 million with
$47 million upfront
July 2010
AGI Dermatics
Sale to
Estée Lauder
Undisclosed
September 2008
ProEthic Pharma
Sale to
Kowa Pharmaceuticals
Undisclosed
April 2008